学 术

分享到微信 ×
打开微信“扫一扫”
即可将网页分享至朋友圈
学术沙龙:Promises and Challenges of Molecular Imaging for Cancer Detection and Image-guided Cancer Therapy
文:教师发展中心 来源:党委教师工作部、人力资源部(教师发展中心) 时间:2017-04-14 3333

  本次“学术沙龙”活动特别邀请美国埃默里大学Lily Yang教授与我校师生共同讨论生物医学成像。具体安排如下,欢迎感兴趣的教师和学生参加。

  一、主 题:Promises and Challenges of Molecular Imaging for Cancer Detection and Image-guided Cancer Therapy

  二、主讲人:美国埃默里大学医学院 讲席教授 Lily Yang

  三、时 间:2017年4月17日(周一)16:00-18:00

  四、地 点:清水河校区图书馆二楼E区多媒体天韵厅

  五、主持人:物理电子学院 奚磊 研究员

  六、交流内容

  Development of novel targeted imaging agents holds great promise for early cancer detection. The ability of noninvasive imaging of biomarker expression in human cancer further offers a means for the application of precision oncology using targeted cancer therapy. We have developed receptor targeted and multi-imaging modality nanoparticles that are targeted to cell surface receptors highly expressed in cancer cells and active tumor stromal cells, such as urokinase plasminogen activator receptor (uPAR) and IGF-1R. This magnetic iron oxide nanoparticle platform coupled with near infrared (NIR) dye labeled targeting ligands has been demonstrated to be excellent NIR optical, MRI, photoacoustic, spectroscopic, and fluorescence tomography contrast agents in preclinical human cancer models in mice. Targeted delivery of the nanoparticles has also been demonstrated in transgenic mouse cancer models. Efficient accumulation of the nanoparticles in the early tumor lesions could be detected by NIR optical and MR imaging. We found that the majority of the receptor targeted nanoparticles in tumor tissues were localized in tumor stroma due to the presence of an intensive stromal barrier that limited nanoparticle delivery into tumor cells, which prevented accurately detection of the level of biomarker expression and efficient drug delivery in tumor cells. Therefore, tumor stromal barrier presents a major challenge for the application of targeted imaging nanoparticles to determine the level of biomarker expression in cancer cells for designing a biomarker targeted therapy.

  七、主讲人简介

YA3GLGT6}$BZP0DA]R56GA0.jpg

  Dr. Lily Yang is Professor and Nancy Panoz Chair of Surgery in Cancer Research at Emory University School of Medicine, Atlanta, Georgia, USA. She received her medical training at West China University of Medical Sciences and the Chinese Academy of Preventive Medicine. She received her PhD degree in Molecular and Cellular Biology from Brown University in 1993.  Dr. Yang’s research focuses on the development of novel nanotechnologies and imaging methods for early cancer detection, targeted drug delivery, non-invasive assessment of therapeutic response, and image-guided surgery. She has published over 90 high-impact journal articles including Nature nanotechnology, Nature biotechnology, Cancer Research, Clinical Cancer Research, Biomaterials et al, authored 8 book chapters, and delivered over 100 academic talks. Now, she is serving as editorial board members of Apoptosis, Breast Cancer-Targets and Therapy, American Journal of Nuclear Medicine and Molecular Imaging, Theranostics, and Journal of Gastroenterology and Hepatology Research.


                     人力资源部教师发展中心

                       2017年4月14日


编辑:胡武辉  / 审核:罗莎  / 发布:林坤

"